AU2017283653C1 — Porphyrin compounds and compositions useful for treating cancer
Assigned to Oncoselect Therapeutics LLC · Expires 2022-05-05 · 4y expired
What this patent protects
A porphyrin compound and composition made therefrom comprising a therapeutically effective dose of a porphyrin hound via a linker to an anti-cancer agent useful in treating cancer in a patient in need thereof or to treat cancer cells in-vitro. The compounds and compositions may b…
USPTO Abstract
A porphyrin compound and composition made therefrom comprising a therapeutically effective dose of a porphyrin hound via a linker to an anti-cancer agent useful in treating cancer in a patient in need thereof or to treat cancer cells in-vitro. The compounds and compositions may be delivered by a drug delivery device as disclosed here and be part of a kit.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.